The aim is to provide the best prostate cancer care in the world at all points of the journey of patients, be it at screening, diagnosis, treatment or through support in their daily life.
We embrace quality-focussed team working to improve outcomes for patients.
Patient care, innovation and research go seamlessly hand-in-hand to lead in all areas of Prostate Cancer.
Cambridge – A leading centre in Prostate Cancer care and research
Prostate cancer services played a key role in the growth of the Urology department at Addenbrooke’s Hospital. We are one of the international leaders in MRI-based diagnostics for Prostate Cancer and have one of the largest UK robotic prostatectomy programmes with published outcome data. Oncological treatments are provided to the highest standards.
Per year we perform:
- over 300 MRI-based diagnostic procedures (the highest number in the UK)
- over 500 radiation treatments
- over 200 robotic prostatectomies with continuing increase in demand (NICE guidance: a centre should do no less than 150/year)
- over 100 brachytherapy procedures
- we offer safe active surveillance with PSA, MRI and targeted biopsies
- 200-300 treatments with hormone- and chemotherapy.
95% of prostate cancer patients treated at CUH live for at least 5 years (UK average 83%; Europe “best” countries overall average 85%). 10 and 20 year survival rates are equally world-leading.
Members of the prostate team have formed a translational Prostate Cancer research collaborative to coordinate their activities in Cambridge.
The following institutions are involved:
- Departments of Oncology, Radiology and the Academic Urology Group at the University of Cambridge
- Departments of Pathology, Radiology, Oncology and Urology at Addenbrookes Hospital
- Cambridge Urology Bio-repository – Cambridge Cancer Centre
- Associations with the Cambridge Institute, the MRC Hutchison and the Sanger Institute
The bio-repository is one of the most comprehensive, with state-of-the-art facilities for analysis and providing information to the International Cancer Genome Consortium.